-+ 0.00%
-+ 0.00%
-+ 0.00%

Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focus

PUBT·08/06/2026 12:20:46
Listen to the news
Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focus
  • Prime Medicine highlighted a near-term focus on in vivo liver programs, led by Wilson disease candidate PM577a and AATD candidate PM647.
  • PM577a received CTA and IND clearance; a Phase 1/2 trial is slated to start in H2 2026, with initial clinical data targeted in 2027.
  • PM647 is expected to have an IND and/or CTA filing in Q3 2026; initial clinical data is targeted in 2027.
  • The company also flagged progress toward a BLA filing for ex vivo CGD program PM359, with a commercial launch planned for 2027+.
  • Pipeline expansion priorities include cystic fibrosis proof-of-concept work and additional strategic partnerships to accelerate development and strengthen funding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.